References
- Parenti F, Beretta G, Berti M, Arioli V. Teichomycins, a new antibiotic from Actinoplanes teichomyceticus nov.sp. I. Description of the producer strains, fermentation studies and biological properties. J Antibiot 1978; 31: 276–8.
- McCormick M H, Stark WM, Pittinger GE, Pittinger RC, Mcguire JM. Vancomycin, a new antibiotic. 1 Chemical and biological properties. In: Welch H, Marti-Ibanez F, Eds., Antibiotics Annual 1955-1956, New York, USA Medical Encyclopaedia Inc., 1956: 606–11.
- Felmingham D. Glycopeptides. In: O’Grady F, Lambert HP, Finch RG. Greenwood D, Eds. Antibiotic and Chemotherapy. New York, USA: Churchill Livingstone Inc. 1997: 363–70.
- Wilson APR, Grüneberg RN. Chemistry, mode of action and antibacterial activity. In: Teicoplanin: The first decade. Abingdon, UK: The Medicine Group (Educational) Ltd. 1997: 11–30.
- Borghi A, Coronelli C, Faniuolo L, Allievi G, Pallanza R, Gallo GG. Teichomycins, new antibiotics from Acinoplames teichomyceticus nov.sp IV. Separation and characterisation of the components of teichomycin (teicoplanin). J Antibiot 1984; 37: 615–20.
- Malabarba A, Strazzolini P, Depaoli A, Landi M, Berti M. Cavalleri B. Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov.sp. VI. Chemical degradation: physicochemical and biological properties of acid hydrolysis products. J Antibiot 1984; 37: 988–99.
- Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Microbiol Infect Dis 1989; 8: 943–50.
- NCCLS. Performance standards for antimicrobial susceptibility testing-Ninth informational supplement. NCCL document M100-S9. NCCLS, Wayne, Pennsylvania, USA, 1999.
- Felmingham D. Glycopeptides: vancomycin and teicoplanin. In: Reeves DS, Wise R, Andrews JM, White LO, Eds, Clinical Antimicrobial Assays, Oxford, UK: Oxford University Press, 1999: 137–48.
- Spencer RC, Goering R. A critical review of the in vitro activity of teicoplanin. Int J Antimicrob Agents 1995; 5: 169–77.
- Uttley AHC, Collins CH, Naidour J, George RC. Vancomycin-resistant enterococci. Lancet 1988; i: 57–8.
- Leclercq R, Derlot E, Duval J, Courvalin P. Plasmidmediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New Engl J Med 1988; 319: 157–61.
- Reynolds PE, Stitger JM. Mechanisms of resistance to glycopeptides in enterococci: the peptidoglycan precursors. In: Brun-Buisson C, Eliopoulos GM, Leclercq R, Eds, Bacterial Resistance to Glycopeptides, Paris, France: Flammarion Médecine Sciences, 1998: 4–12.
- Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide- resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997; 41: 2016–18.
- Billot-Klein D, Schlaes D, Gutmann L. Peptidoglycan structure of glycopeptide-resistant enterococci and Staphylococcus haemolyticus. In: Brun-Buisson C, Eliopoulos GM, Leclercq R. Eds, Bacterial Resistance to Glycopeptides. Paris, France: Flammarion Médecine Sciences, 1998: 28–38.
- Hiramatsu K, Hanaki H. Glycopeptide resistance in staphylococci. Curr Opin Infect Dis 1998; 11: 653–58.
- Arthur M, Baptista M, Depardieu F, et al. Regulation of glycopeptide resistance in enterococci. In: Brun-Buisson C, Eliopoulos GM, Leclercq R. Eds, Bacterial Resistance to Glycopeptides Paris, France: Flammarion Médecine Sciences, 1998: 13–25.
- Tenover FC, Gaynes R. Dissemination of vancomycinresistant enterococci in the United States. In: Brun-Buisson C, Eliopoulos GM, Leclercq R. Eds, Bacterial Resistance to Glycopeptides, Paris, France: Flammarion Médecine Sciences, 1998: 101–10.
- Felmingham D, Brown DFJ, Soussy CJ, & the European Glycopeptide Resistance Survey Study Group. European Glycopeptide Susceptibility Survey of Gram-Positive Bacteria for 1995. Diagn Microbiol Infect Dis 1998; 31: 563–71.